UNSPSC 51350000: Estrogens and progestins and internal contraceptives

This classification denotes a wide variety of drugs that fall into two structural and one modal category. The first category concerns compounds that interact with estrogen receptors in target tissues to bring about the effects similar to those of estradiol. Estrogens stimulate the female reproductive organs, and the development of secondary female sex characteristics. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.

The second category contains compounds that interact with progesterone receptors in target tissues to bring about the effects similar to those of progesterone. The third category oor mode concerns chemical substances that prevent or reduce the probability of conception.

UNSPSC 51350000 Estrogens and progestins and internal contraceptives is a Family code under which state and local governments procure generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing agreements. The single recent opportunity in the dataset — Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 — reveals that the code actually captures a broad portfolio of pharmaceutical products beyond the code's nominal scope. Issuers are state procurement offices administering multi-jurisdictional cooperative purchasing vehicles; MMCAP itself, administered by the Minnesota Department of Administration's Office of State Procurement, coordinates contracting across participating state and local government facilities in Minnesota and Oregon. Vendors must supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and maintain contractual relationships with at least two of the three. Products must be available in the marketplace by May 15, 2026, and awarded agreements become effective July 1, 2026. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain comprehensive insurance coverage including commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000, and offer pricing in formats such as flat price, net price (NF30, NF60, NF90), or WAC-minus structures. The contract term is two years for new vendors, with optional extensions at MMCAP's discretion; incumbent responders' amendments align with existing agreement expiration dates through June 30, 2028.

The MMCAP RFP represents the primary recent activity visible under this code. The Minnesota Department of Administration and participating state and local government facilities across Minnesota and Oregon are the buying parties; no other states or jurisdictions appear in the recent-opportunities block. Proposals closed March 26, 2026, with a question cutoff of February 18, 2026. Evaluation criteria weighted price competitiveness at 75 percent, fixed pricing for the contract term at 10 percent, and compliance with administrative data format, electronic data interchange capability, and agreement to a 3 percent administrative fee at 5 percent each. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations, product availability, patient safety, and member-specific needs. The RFP documentation does not disclose specific award values or budget ranges, nor does it identify set-aside designations limiting responses to particular business classifications or disadvantaged enterprises.